Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes

NCT03637868 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT03637868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03637868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 2
Overall status
Withdrawn
Start date
February 26, 2019
Completion date
April 14, 2020
Enrollment
0 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer